EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin



Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin



Infection and Immunity 58(6): 1606-1613



The lethal toxin of Bacillus anthracis consists of two components, protective antigen and lethal factor. Protective antigen is cleaved after binding to cell receptors, yielding a receptor-bound fragment that binds lethal factor. Sixty-one monoclonal antibodies to the lethal factor protein have been characterized for specificity, antibody subtype, and ability to neutralize lethal toxin. Three monoclonal antibodies (10G3, 2E7, and 3F6) neutralized lethal toxin in Fisher 344 rats. However, in a macrophage cytolysis assay, monoclonal antibodies 10G3, 2E7, 10G4, 10D4, 13D10, and 1D8, but not 3F6, were found to neutralize lethal toxin. Binding studies showed that five of the monoclonal antibodies that neutralized lethal toxin in the macrophage assay (10G3, 2E7, 10G4, 10D4, and 13D10) did so by inhibiting the binding of lethal factor to the protective antigen fragment bound to cells. Monoclonal antibody 1D8, which was also able to neutralize lethal toxin activity after lethal factor was prebound to cell-bound protective antigen, only partially inhibited binding of lethal factor to protective antigen. Monoclonal antibody 3F6 did not inhibit the binding of lethal factor to protective antigen. A competititve-binding enzyme-linked immunosorbent assay showed that at least four different antigenic regions on lethal factor were recognized by these seven neutralizing hybridomas. The anomalous behavior of 3F6 suggests that it may induce a conformational change in lethal factor. Differences in neutralizing activity of monoclonal antibodies were related to their relative affinity and epitope specificity and the type of assay.

(PDF emailed within 1 workday: $29.90)

Accession: 007689949

Download citation: RISBibTeXText

PMID: 2111283



Related references

Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infection and Immunity 77(1): 162-169, 2008

Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay. Clinical and Vaccine Immunology 15(11): 1737-1741, 2008

Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infection and Immunity 56(7): 1807-1813, 1988

Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo. Fems Immunology and Medical Microbiology 62(1): 11-22, 2011

Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142: 707-715, 1996

Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Clinical and Vaccine Immunology 15(1): 71-75, 2007

CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies. Infection and Immunity 78(4): 1610-1617, 2010

In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infection and Immunity 75(11): 5443-5452, 2007

Activated protein C ameliorates Bacillus anthracis lethal toxin-induced lethal pathogenesis in rats. Journal of Biomedical Science 19: 98-98, 2013

Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infection and Immunity 45(3): 761-767, 1984

Efficient production and characterization of Bacillus anthracis lethal factor and a novel inactive mutant rLFm-Y236F. Protein Expression and Purification 59(1): 25-30, 2008

Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. Journal of Bacteriology 83: 1274-1280, 1962

Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infection and Immunity 75(11): 5425-5433, 2007

In vivo delivery by recombinant Bacillus anthracis of a fusion protein composed of the tetanus toxin fragment C and anthrax toxin lethal factor. IJMM International Journal of Medical Microbiology 290(4-5, Supplement 30): A76, October, 2000

Detection of functional domains in the molecule of the lethal factor of Bacillus anthracis toxin. Molekulyarnaya Genetika Mikrobiologiya i Virusologiya 0(3): 20-22, 1996